These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 21442459

  • 1. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.
    Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
    [Abstract] [Full Text] [Related]

  • 2. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 4. Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
    Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, Moericke R, Kann PH.
    Osteoporos Int; 2012 Jul; 23(7):2043-51. PubMed ID: 22086310
    [Abstract] [Full Text] [Related]

  • 5. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 6. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W, Sun J, Zhou L, Li Y, Wu X.
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [Abstract] [Full Text] [Related]

  • 10. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 11. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
    McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL.
    Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099
    [Abstract] [Full Text] [Related]

  • 13. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
    Yoshioka T, Okimoto N, Okamoto K, Sakai A.
    J Bone Miner Metab; 2013 Mar; 31(2):153-60. PubMed ID: 23076293
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
    Moriwaki K, Mouri M, Hagino H.
    Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
    [Abstract] [Full Text] [Related]

  • 15. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 16. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V, Arce-Salinas CA, Espinosa-Ortega F.
    J Clin Densitom; 2014 Feb; 17(4):484-9. PubMed ID: 24613450
    [Abstract] [Full Text] [Related]

  • 17. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED, Perry CM.
    Drugs Aging; 2008 Jun; 25(11):963-86. PubMed ID: 18947264
    [Abstract] [Full Text] [Related]

  • 19. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R.
    J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A.
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.